Dechra Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 1/6

Dechra Pharmaceuticals hat ein Gesamteigenkapital von £755.2M und eine Gesamtverschuldung von £487.6M, wodurch sich der Verschuldungsgrad auf 64.6% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen £1.6B bzw. £814.2M. Dechra Pharmaceuticals Das EBIT des Unternehmens beträgt £17.1M, so dass der Zinsdeckungsgrad 0.8 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von £74.4M.

Wichtige Informationen

64.6%

Verhältnis von Schulden zu Eigenkapital

UK£487.60m

Verschuldung

Zinsdeckungsgrad	0.8x
Bargeld	UK£74.40m
Eigenkapital	UK£755.20m
Gesamtverbindlichkeiten	UK£814.20m
Gesamtvermögen	UK£1.57b

Jüngste Berichte zur Finanzlage

Dechra Pharmaceuticals (LON:DPH) Takes On Some Risk With Its Use Of Debt

May 31

We Think Dechra Pharmaceuticals (LON:DPH) Is Taking Some Risk With Its Debt

Mar 02

These 4 Measures Indicate That Dechra Pharmaceuticals (LON:DPH) Is Using Debt Reasonably Well

Jun 10

Here's Why Dechra Pharmaceuticals (LON:DPH) Can Manage Its Debt Responsibly

Dec 04

Recent updates

Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At £0.3289

Sep 08

Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Aug 18

Do Dechra Pharmaceuticals' (LON:DPH) Earnings Warrant Your Attention?

Aug 02

These 4 Measures Indicate That Dechra Pharmaceuticals (LON:DPH) Is Using Debt Reasonably Well

Jun 10

Calculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)

May 08

Do Dechra Pharmaceuticals's (LON:DPH) Earnings Warrant Your Attention?

Apr 22

Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To UK£0.12

Feb 23

Is Dechra Pharmaceuticals PLC (LON:DPH) Expensive For A Reason? A Look At Its Intrinsic Value

Jan 29

Is Now The Time To Put Dechra Pharmaceuticals (LON:DPH) On Your Watchlist?

Jan 11

Here's Why Dechra Pharmaceuticals (LON:DPH) Can Manage Its Debt Responsibly

Dec 04

It Looks Like Shareholders Would Probably Approve Dechra Pharmaceuticals PLC's (LON:DPH) CEO Compensation Package

Oct 15

Dechra Pharmaceuticals' (LON:DPH) Upcoming Dividend Will Be Larger Than Last Year's

Sep 25

Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At UK£0.29

Sep 11

With EPS Growth And More, Dechra Pharmaceuticals (LON:DPH) Is Interesting

Sep 08

Is Dechra Pharmaceuticals PLC (LON:DPH) Worth UK£43.4 Based On Its Intrinsic Value?

Jun 17

Is Dechra Pharmaceuticals PLC (LON:DPH) A Smart Choice For Dividend Investors?

Apr 09

Dechra Pharmaceuticals (LON:DPH) Has A Pretty Healthy Balance Sheet

Mar 05

Are Dechra Pharmaceuticals' (LON:DPH) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 17

Dechra Pharmaceuticals PLC (LON:DPH) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Feb 02

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: DPHDie kurzfristigen Aktiva des Unternehmens (£467.9M) übersteigen seine kurzfristigen Passiva (£164.0M).

Langfristige Verbindlichkeiten: DPHDie kurzfristigen Vermögenswerte des Unternehmens (£467.9M) decken seine langfristigen Verbindlichkeiten (£650.2M) nicht.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: DPHDie Nettoverschuldung im Verhältnis zum Eigenkapital (54.7%) wird als hoch angesehen.

Schulden abbauen: DPHDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 57.6% auf 64.6% gestiegen.

Schuldendeckung: DPHDie Schulden des Unternehmens sind nicht ausreichend durch den operativen Cashflow (13%) gedeckt.

Zinsdeckung: DPHDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (0.8x Deckung) nicht gut gedeckt.

Dechra Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Intends to Delist from Official List

Dechra Pharmaceuticals (LON:DPH) Takes On Some Risk With Its Use Of Debt

We Think Dechra Pharmaceuticals (LON:DPH) Is Taking Some Risk With Its Debt

These 4 Measures Indicate That Dechra Pharmaceuticals (LON:DPH) Is Using Debt Reasonably Well

Here's Why Dechra Pharmaceuticals (LON:DPH) Can Manage Its Debt Responsibly

Recent updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

Dechra Pharmaceuticals (LON:DPH) Takes On Some Risk With Its Use Of Debt

A Look At The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Consensus EPS estimates fall by 10%

We Think Dechra Pharmaceuticals (LON:DPH) Is Taking Some Risk With Its Debt

Dechra Pharmaceuticals' (LON:DPH) Dividend Will Be Increased To £0.125

Upcoming dividend of UK£0.13 per share at 1.6% yield

First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.38 in 1H 2022)

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Now 22% undervalued after recent price drop

Now 21% undervalued after recent price drop

Less than half of directors are independent

Upcoming dividend of UK£0.33 per share

Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To £0.3289

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Dechra Pharmaceuticals (LON:DPH) Is Paying Out A Larger Dividend Than Last Year

Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At £0.3289

Full year 2022 earnings: EPS misses analyst expectations

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Do Dechra Pharmaceuticals' (LON:DPH) Earnings Warrant Your Attention?

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Now 21% undervalued after recent price drop

These 4 Measures Indicate That Dechra Pharmaceuticals (LON:DPH) Is Using Debt Reasonably Well

Dechra Pharmaceuticals PLC Announces Executive Changes

Calculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Less than half of directors are independent

Do Dechra Pharmaceuticals's (LON:DPH) Earnings Warrant Your Attention?

Non-Executive Chairman recently bought UK£99k worth of stock

Consensus EPS estimates increase by 17%

Upcoming dividend of UK£0.12 per share

Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To UK£0.12

First half 2022 earnings: EPS misses analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Is Dechra Pharmaceuticals PLC (LON:DPH) Expensive For A Reason? A Look At Its Intrinsic Value

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Is Now The Time To Put Dechra Pharmaceuticals (LON:DPH) On Your Watchlist?

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Here's Why Dechra Pharmaceuticals (LON:DPH) Can Manage Its Debt Responsibly

Non-Executive Director Denise Goode has left the company

Upcoming dividend of UK£0.29 per share

It Looks Like Shareholders Would Probably Approve Dechra Pharmaceuticals PLC's (LON:DPH) CEO Compensation Package

CFO & Executive Director exercised options and sold UK£102k worth of stock

Dechra Pharmaceuticals' (LON:DPH) Upcoming Dividend Will Be Larger Than Last Year's

CEO, MD & Executive Director exercised options and sold UK£841k worth of stock

Board Member recently sold UK£875k worth of stock

Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At UK£0.29

With EPS Growth And More, Dechra Pharmaceuticals (LON:DPH) Is Interesting

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Consensus EPS estimates increase to UK£0.52

Price target increased to UK£44.46

Is Dechra Pharmaceuticals PLC (LON:DPH) Worth UK£43.4 Based On Its Intrinsic Value?